Abstract: The present invention relates to a pharmaceutical pellet composition having a core element including at least one highly soluble active ingredient and a core coating which is partially soluble at a highly acidic pH. The pharmaceutical composition provides a slow release of active ingredient at a highly acidic pH and provides a constant, relatively faster rate of release at a more alkaline pH such as that of the intestine. Oral administration of the pharmaceutical pellet composition of the present invention to a patient is effective to deliver to the blood levels of active ingredient within the therapeutic range and to maintain such levels over an extended period of time.
Abstract: Prothrombin time reagents are provided which comprise novel liposome compositions in which tissue factor is associated with an inserted into the phospholipid bilayer of the liposomes. Methods for their preparation are also provided. The liposome compositions may be adjusted to allow maximum coagulant activity and sensitivity to extrinsic coagulation factors.
Abstract: The invention is a resorbable, viscous to solid wax for the mechanical staunching of blood on hard body tissue, particularly bones, based on oligomers of glycolic acid and/or lactic acid and derivatives thereof with monofunctional and/or polyfunctional alcohols and/or corresponding carboxylic acids. The new waxes are characterized by containing body-compatible salts of organic and/or inorganic acids which are formed by corresponding reaction of any free carboxyl groups present in the oligomer wax and/or are incorporated in the wax in homogeneous distribution as added salts.
Abstract: Patients suffering vascular injury as a result of balloon catheterization or the like are treated with medicaments containing conjugates comprising a ligand, such as bFGF (or another FGF polypeptide), and a cytotoxic agent. The cytotoxic agent can be a ribosome-inactivating protein (RIP), such as saporin, which is attached to the ligand through a chemical bond or prepared as a recombinant DNA chimera. The medicament containing the conjugate is administered IV to patients after they have been treated for atherosclerosis in a manner which commonly results in vascular injury, particularly to the intima, and effectively prevents restenosis. The conjugate kills proliferating smooth muscle cells in the lumen of the blood vessels which surprisingly express large numbers of high-affinity bFGF receptors while not inhibiting the growth of endothelial cells.
Type:
Grant
Filed:
July 16, 1992
Date of Patent:
May 3, 1994
Assignee:
The Salk Institute for Biological Studies
Inventors:
Ward M. Casscells, Douglas A. Lappi, J. Andrew Baird
Abstract: The present invention is a novel method of producing a unique device of stable porous and membraneless nanomatrixes for carrying medication for in vivo administration. The present invention method produces the device of stable nanomatrixes by mixing a first type of protein which is hemoglobin, a second type of protein which is albumin, and a solution containing an organic solvent which is an alcohol, where the weight ratio of the first and second type of proteins is within the range of approximately 92.+-.5 to 8.+-.5. This results in a turbid suspension of monodispersed nanomatrixes which are typically larger than 1 micron but less than 4 microns in diameter and stable against aggregation and re-solubilization in hypotonic saline for at least 24 hours. An additional solution containing a biologically active substance may be added before or after the solution containing an organic solvent, such that the biologically active substance is entrapped within or bound on the surfaces of the nanomatrixes.
Abstract: Ferritin analogs comprising an apoferritin protein shell and a core substantially devoid of ferrihydrite, e.g. of inorganic composition such as aluminum hydroxide or organic composition such as acetaminophen. The protein shell can be removed from ferritin analog to produce spherules having a substantially monomodal nominal diameter between about 45 and 100 Angstroms.
Abstract: A polymer for a prolonged release preparation which comprises(A) a polylactic acid and(B) a copolymer of glycolic acid and a hydroxycarboxylic acid of general formula ##STR1## wherein R stands for an alkyl group having 2 to 8 carbons, wherein the weight ratio of (A) and (B) is in the range of 10/90 to 90/10. The drug is released at a constant rate from the preparation over the total release period without a large burst at the initial state. Furthermore, the drug release period of the preparation can be freely controlled by varying the blending ratio of (A) and (B).
Abstract: A process for preparing spray granules or microgranules, which contain no binder, are non-dusting and free-flowing, from finely divided pure riboflavin, comprises subjecting an aqueous or water-containing suspension of the pure finely divided riboflavin toa) a fluidized bed spray dryingb) a single-nozzle spray drying orc) a disk-type spray dryingin particular a fluidized bed spray drying, without adding binders to the suspension, and the spray granules or microgranules of riboflavin obtainable by this process.
Type:
Grant
Filed:
July 28, 1992
Date of Patent:
April 5, 1994
Assignee:
BASF Aktiengesellschaft
Inventors:
Johannes Grimmer, Hans Kiefer, Christoph Martin
Abstract: A disinfectant or preservative composition particularly adapted for use in ophthalmic preparations such as contact lens disinfecting, cleaning, cushioning, wetting, soaking and reconditioning solutions and additionally in topical medications and tear substitutes, which uses a hydrophilic polymeric antimicrobial agent, namely poly[oxyethylene(dimethylimino) (ethylene dimethylimino)ethylene dichloride] with additional agents including EDTA and alkali salts thereof and a boric acidborate buffer system.
Abstract: Osteoprogenitor cells encapsulated in alginate and alternatively, additionally encapsulated in poly-L-lysine and/or agarose promote regeneration of bone at the site of implantation. The present invention provides a composition comprising osteoprogenitor cells embedded or encapsulated in alginate and the use of said microcapsules for the facilitation of bone regeneration.
Type:
Grant
Filed:
January 2, 1992
Date of Patent:
March 15, 1994
Assignee:
Southwest Research Institute
Inventors:
Herman W. Schlameus, William C. Fox, Donald J. Mangold, Robert G. Triplett, George R. Holt, Thomas B. Aufdemorte
Abstract: Composition for promoting healing containing, as a healing agent, nonionic vesicles obtained from a lipid mixture containing at least one nonionic lipid having the formula; ##STR1## wherein R is either at least one C.sub.16 -C.sub.18 radical, or R'CO wherein R' is at least one C.sub.15 -C.sub.17 alkyl radical, in combination with cholesterol and, optionally, dicetylphosphate or tetracetylphospate.This composition can be used topically to accelerate the scarring of wounds.
Type:
Grant
Filed:
May 13, 1992
Date of Patent:
March 1, 1994
Assignee:
L'Oreal
Inventors:
Alexandre Zysman, Henri Sebag, Guy Vanlerberghe, Rose-Marie Handjani, Alain Ribier
Abstract: Compositions, for example cosmetic or pharmaceutical compositions, and methods of increasing melanin formation on the skin or scalp employ liposomes including between 0.001 and 10 weight percent, with respect to the total weight of the composition, of tyrosine or a tyrosine derivative selected from the group consisting of an alkali metal salt of L-tyrosine, an alkaline earth metal salt of L-tyrosine, methyl L-tyrosinate, ethyl L-tyrosinate, and stearyl L-tyrosinate.
Abstract: A pretreatment conditioner comprising an aqueous system of from about 0.1 to about 20 weight percent of a cationic cellulose derivative quaternized with fatty C.sub.10 -C.sub.18 alkyl groups, from about 0.05 to about 20 weight percent of a quaternary polymer; and (3) from about 0.02 to about 10 weight percent of a quaternary ammonium salt, with each weight percentage reflecting the active weight percent of the ingredient, based on the total weight of the composition. The composition is useful in a method of pretreatment conditioning of hair comprising applying to hair the composition followed by shampooing with an anionic shampoo.
Abstract: Disclosed is a treated material including a base material such as an extrudate, a woven fabric, or unwoven fibers, a disperse dye-type molecule such as a dye or antibiotic dispersed within and non-covalently adhered to the base material, and a molecule-of-interest immobilized on the base material by way of a reactive group on the disperse dye-type molecule. Also disclosed are methods of producing the treated material.
Type:
Grant
Filed:
June 21, 1991
Date of Patent:
January 25, 1994
Assignee:
New England Deaconess Hospital Corporation
Abstract: A triggered release liposomal delivery system is disclosed that selectively releases its contents in response to illumination or reduction in pH. The liposomes contain an amphipathic lipid, such as a phospholipid, having two chains derived from fatty acid that allow the lipid to pack into a bilayer structure. One or both of the alkyl chains contains a vinyl ether functionality that is cleaved by reactive oxygen species (ROS) or acid. A photosensitizer is incorporated into the liposomal cavity or membrane, and produces ROS or acid when illuminated to cleave the vinyl ether functionality and disrupt the liposomal membrane to release the vesicle contents. The lipid is preferably a plasmalogen, for example ##STR1## wherein R.sub.1 and R.sub.2 are each long chain hydrocarbons containing 12-24 carbons.
Abstract: Methods for preventing and treating corneal haze resulting from exposure of the eye to laser irradiation are disclosed. The methods include administration of compositions of wound healing modulators to the eye. Compositions for use in preventing and treating the corneal haze are also disclosed.
Type:
Grant
Filed:
April 10, 1992
Date of Patent:
December 21, 1993
Assignee:
Alcon Laboratories, Inc.
Inventors:
Stella M. Robertson, Herman M. Kunkle, Jr.
Abstract: Disclosed are lyophilized gonadotropin containing preparations containing a dicarboxylic acid salt stabilizer. The particular proteins (e.g. LH, TSH, FSH, or HCG) are in admixture with, and at least partially capable of stabilization by, the particular stabilizer in lyophilized form. The preparations contain a sufficient amount of dicarboxylic acid salt to stabilize the protein in freeze-dried form for a desired time at a desired temperature. Typical dicarboxylic acid salts disclosed are the salts of citric, tartaric, and aspartic acids. The preparations preferably include a non-reducing disaccharide to increase the collapse temperature of the solution to be lyophilized. Methods of making the preparations in lyophilized form and the resulting injectable preparations are also disclosed.
Type:
Grant
Filed:
July 13, 1992
Date of Patent:
December 14, 1993
Assignee:
Akzo N.V.
Inventors:
Andreas L. J. de Meere, Marinus A. De Ruiter
Abstract: The invention relates to pharmaceutical compositions in the form of parenterally, especially intravenously, administrable liposome dispersions or dry preparations, especially lyophilisates, that can be used therefor, comprising the zinc-phthalocyanine complex and synthetic, substantially pure phospholipids.
Type:
Grant
Filed:
December 9, 1992
Date of Patent:
December 14, 1993
Assignee:
Ciba-Geigy Corp.
Inventors:
Peter Schneider, Peter van Hoogevest, Hans G. Capraro, Ute Isele
Abstract: Disclosed is an anticoagulant material comprising a polymer obtained from an ionically bonded composite synthesized from i) a basic compound having a copolymerizable functional group and ii) a heparin salt. Disclosed is also a process for preparing the anticoagulant material. The anticoagulant material of the present invention can maintain excellent anticoagulant properties or antithrombotic properties over a long period of time and is capable of being applied as a component material for various medical articles such as artificial internal organs and artificial blood vessels, and a process for preparing it.
Abstract: A method for treating an infection caused by an intracellular parasite in a patient. The method includes administering to the patient liposomes coated with C-reactive protein, wherein the liposomes include phosphatidylcholine or phosphorylcholine.
Type:
Grant
Filed:
April 19, 1991
Date of Patent:
December 14, 1993
Assignee:
New England Medical Center Hospitals, Inc.
Inventors:
Jeffrey A. Gelfand, Michael V. Callahan, Yoshinori Yamada